2021
DOI: 10.1200/jco.2021.39.3_suppl.277
|View full text |Cite
|
Sign up to set email alerts
|

Exploring the diagnostic journey and life impact of patients with cholangiocarcinoma (CCA): Results from a large patient survey in the United States.

Abstract: 277 Background: Patients (pts) with CCA typically present with advanced disease and face a poor prognosis and impaired quality of life (QoL). Despite improvements in therapies, the impact of CCA on pts’ daily lives has been rarely studied. This pt-focused survey explored the diagnostic journey, life impact including work status, QoL and psychosocial impacts of CCA. Methods: Pts with CCA were recruited in partnership with the Cholangiocarcinoma Foundation from Aug 23 through Sept 20, 2019, and were categorized… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Optimized plans to predict the diagnosis of iCCA at an early stage (resectable) are critical to further improve patient care [ 43 ]. Strikingly, a recent study involving patients with CCA ( n = 707) showed that the median duration from symptom onset to CCA diagnosis was 19 months (range, 1 to 241) and initial misdiagnosis occurred in 35% of patients ( n = 247) [ 14 ].…”
Section: Identifying Potential Challenges and Solutions For Optimal Treatment Of Patients With Iccamentioning
confidence: 99%
See 1 more Smart Citation
“…Optimized plans to predict the diagnosis of iCCA at an early stage (resectable) are critical to further improve patient care [ 43 ]. Strikingly, a recent study involving patients with CCA ( n = 707) showed that the median duration from symptom onset to CCA diagnosis was 19 months (range, 1 to 241) and initial misdiagnosis occurred in 35% of patients ( n = 247) [ 14 ].…”
Section: Identifying Potential Challenges and Solutions For Optimal Treatment Of Patients With Iccamentioning
confidence: 99%
“…However, there are potential barriers to the implementation of precision medicine in patients with CCA. The barriers may include delays in CCA diagnosis, hurdles associated with tissue acquisition for biomarker testing, ineffective collaboration between the hepatobiliary multidisciplinary team (MDT), and lack of awareness of the importance of biomarker testing [ 14 , 15 , 16 , 17 , 18 ]. The integral role of an effective MDT for the diagnosis and optimal treatment of patients with cancer, including CCA, is essential in both the community and academic settings; however, challenges associated with optimal patient care remain, which highlight the need for improvement [ 19 , 20 , 21 , 22 , 23 ].…”
Section: Introductionmentioning
confidence: 99%